1. |
Vadlapudi AD, Vadlapatla RK, Mitra AK. Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents[J]. Recent Pat Antiinfect Drug Discov, 2012, 7(1): 8-18. DOI: 10.2174/157489112799829765.
|
2. |
Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis[J/OL]. Rev Med Virol, 2019, 29(3): e2034[2019-01-31]. https://pubmed.ncbi.nlm.nih.gov/30706584/. DOI: 10.1002/rmv.2034.
|
3. |
Munro M, Yadavalli T, Fonteh C, et al. Cytomegalovirus retinitis in HIV and non-HIV Individuals[J]. Microorganisms, 2020, 8(1): 55. DOI: 10.3390/microorganisms8010055.
|
4. |
Pearce WA, Yeh S, Fine HF. Management of cytomegalovirus retinitis in HIV and non-HIV patients[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(2): 103-107. DOI: 10.3928/23258160-20160126-01.
|
5. |
Shapira Y, Mimouni M, Vishnevskia-Dai V. Cytomegalovirus retinitis in HIV-negative patients - associated conditions, clinical presentation, diagnostic methods and treatment strategy[J/OL]. Acta Ophthalmol, 2018, 96(7): e761-e767[2017-10-25]. https://pubmed.ncbi.nlm.nih.gov/29068151/. DOI: 10.1111/aos.13553.
|
6. |
Choopong P, Vivittaworn K, Konlakij D, et al. Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis[J/OL]. BMC Infect Dis, 2016, 16: 16164[2016-04-18]. https://pubmed.ncbi.nlm.nih.gov/27090644/. DOI: 10.1186/s12879-016-1490-6.
|
7. |
Smith IL, Macdonald JC, Freeman WR, et al. Cytomegalovirus (CMV) retinitis activity is accurately reflected by the presence and level of CMV DNA in aqueous humor and vitreous[J]. J Infect Dis, 1999, 179(5): 1249-1253. DOI: 10.1086/314710.
|
8. |
Qian Z, Chen X, Tao Y, et al. Prognostic factors of cytomegalovirus infection associated retinitis in HIV-negative patients: a retrospective cohort study[J]. Ocul Immunol Inflamm, 2021, 29(1): 154-159. DOI: 10.1080/09273948.2019.1659978.
|
9. |
Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease[J]. J Infect Dis, 2002, 186(6): 829-833. DOI: 10.1086/342601.
|
10. |
Miao H, Tao Y, Jiang YR, et al. Multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis after stem-cell transplantation[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(7): 1829-1833. DOI: 10.1007/s00417-013-2368-6.
|
11. |
Jeon S, Lee WK. Cytomegalovirus retinitis in a human immunodeficiency virus-negative cohort: long-term management and complications[J]. Ocul Immunol Inflamm, 2015, 23(5): 392-399. DOI: 10.3109/09273948.2014.985385.
|
12. |
Zhang C, Wang YE, Miao H, et al. Efficacy and safety of aqueous interleukin-8-guided treatment in cytomegalovirus retinitis after bone marrow hematopoietic stem cell transplantation[J]. Ocul Immunol Inflamm, 2020, 16: 1-8. DOI: 10.1080/09273948.2020.1823422.
|
13. |
余盈盈, 赵明威, 苗恒. 基于房水病毒学和炎性细胞因子检测的巨细胞病毒性视网膜炎治疗模式的初步研究[J]. 中华眼底病杂志, 2020, 36(1): 1-4. DOI: 10.3760/cma.j.issn.1005-1015.2020.01.001.Yu YY, Zhao MW, Miao H. Regime for cytomegalovirus retinitis based on aqueous virology and inflammatory cytokine determination[J]. Chin J Ocul Fundus Dis, 2020, 36(1): 1-4. DOI: 10.3760/cma.j.issn.1005-1015.2020.01.001.
|
14. |
Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study[J]. Blood, 1996, 88(10): 4063-4071. DOI: 10.1182/blood.V88.10.4063.bloodjournal88104063.
|
15. |
Gerna G, Zavattoni M, Percivalle E, et al. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection[J]. J Clin Microbiol, 1998, 36(4): 1113-1116. DOI: 10.1128/Jcm.36.4.1113-1116.1998.
|
16. |
Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes[J]. Blood, 2001, 97(4): 867-874. DOI: 10.1182/blood.v97.4.867.
|